HCV

US-based AbbVie has received marketing authorisation from European Commission (EC) for its all-oral, short-course, interferon-free treatment of Viekirax (ombitasvir / paritaprevir / ritonavir tablets) and Exviera (dasabuvir tablets) to treat patients with chronic hepatitis C.

Approval was granted with or without ribavirin (RBV) to treat patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis HIV-1 co-infection, patients on opioid substitution therapy and liver transplant recipients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The drug also received approval for use with RBV in genotype 4 (GT4) chronic hepatitis C patients.

AbbVie board chairman Richard Gonzalez said: "The approval of AbbVie’s hepatitis C treatment in the European Union, following the recent approvals in the US and Canada, offers patients across Europe a new and effective treatment to cure this serious disease.

"Approval was based on a clinical development programme, designed to evaluate safety and efficacy of the regimen in 2,300 enrolled patients across 25 countries."

"We are committed to working with local governments and healthcare systems to support broad access to Viekirax and Exviera."

See Also:

Approval was based on a clinical development programme, designed to evaluate safety and efficacy of the regimen in 2,300 enrolled patients across 25 countries.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The programme comprised six pivotal Phase III trials, which demonstrated Viekirax and Exviera cured 95%-100% of hepatitis C patients with GT1 HCV infection who received the recommended regimen, with less than 2% of patients experiencing virologic failure, noted AbbVie.

AbbVie chief scientific officer Michael Severino said: "With the approval of Viekirax and Exviera in the European Union, we are offering a treatment that achieved high cure rates for people living with GT1 and GT4 chronic hepatitis C."

According to AbbVie, Viekirax and Exviera are the first products that received approval as a combination treatment of three direct-acting antivirals, with distinct mechanisms of action and non-overlapping resistance profiles to target hepatitis C at multiple steps in the viral lifecycle.

Image: Electron micrographs of hepatitis C virus purified from cell culture. Photo: courtesy of Maria Teresa Catanese, Martina Kopp, Kunihiro Uryu and Charles Rice.